Lipocine Inc (LPCN): Well, "BioSpecialist" we'll see very soo...

Reply Private New

Next 10 Prev Next

gi197845

Send PM Follow Ignore

Followers	5
Posts	2466
Boards Moderated	0
Alias Born	08/16/2016

gi197845

Re: BioSpecialist post# 252

Tuesday, 01/02/2018 2:23:08 PM

Tuesday, January 02, 2018 2:23:08 PM

Well, "BioSpecialist" we'll see very soon, if you truly deserve the name...BioSpecialist.

Keep Last Read

Next 10 Prev Next

Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:

Detailed Quote

Recent LPCN News

Lipocine Announces Completion of Dosing in Pivotal Study of Postpartum Depression Candidate, LPCN 1154 • PR Newswire (US) • 05/01/2024 12:00:00 PM
Lipocine Announces Positive LPCN 2401 Clinical Results Showing Improved Body Composition in Participants with Obesity • PR Newswire (US) • 04/11/2024 11:00:00 AM
Lipocine Announces Positive Week 52 Results from LPCN 1148 Phase 2 Study in Patients with Cirrhosis • PR Newswire (US) • 03/28/2024 12:00:00 PM
Lipocine Announces First Cohort Dosed in Pivotal Study of LPCN 1154 • PR Newswire (US) • 03/25/2024 12:00:00 PM
Form 8-K - Current report • Edgar (US Regulatory) • 03/07/2024 10:31:06 PM
Lipocine Announces Financial Results for the Full Year Ended December 31, 2023 • PR Newswire (US) • 03/07/2024 01:00:00 PM
Form 8-K - Current report • Edgar (US Regulatory) • 03/07/2024 11:08:06 AM
Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 03/07/2024 11:07:26 AM
Lipocine to Present at 36th Annual Roth Conference • PR Newswire (US) • 03/06/2024 01:00:00 PM
Form 8-K - Current report • Edgar (US Regulatory) • 03/06/2024 11:01:31 AM
Form 8-K - Current report • Edgar (US Regulatory) • 02/12/2024 09:10:26 PM
Lipocine Announces Confirmation of Dosing Regimen for Pivotal Study of LPCN 1154 • PR Newswire (US) • 02/06/2024 01:00:00 PM
Lipocine Announces Continued Commercialization of TLANDO® through Verity Pharmaceuticals • PR Newswire (US) • 02/02/2024 01:00:00 PM
Form 8-K - Current report • Edgar (US Regulatory) • 01/18/2024 01:20:46 PM
Lipocine and Verity Pharma Enter into License Agreement for TLANDO® Franchise in the U.S. and Canada • PR Newswire (US) • 01/18/2024 01:00:00 PM
Form 8-K - Current report • Edgar (US Regulatory) • 12/19/2023 03:00:12 PM
Lipocine to Present at Biotech Showcase 2024 • PR Newswire (US) • 12/19/2023 01:00:00 PM
Form S-3 - Registration statement under Securities Act of 1933 • Edgar (US Regulatory) • 11/22/2023 09:15:57 PM
Form 8-K - Current report • Edgar (US Regulatory) • 11/13/2023 07:45:33 PM
Lipocine Releases Late Breaking Presentation on LPCN 1148 Phase 2 Results at The Liver Meeting® 2023 • PR Newswire (US) • 11/13/2023 07:45:00 PM
Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/08/2023 06:15:13 PM
Form 8-K - Current report • Edgar (US Regulatory) • 11/08/2023 02:50:30 PM
Lipocine Announces Financial Results for the Third Quarter Ended September 30, 2023 • PR Newswire (US) • 11/08/2023 01:00:00 PM
Form 8-K - Current report • Edgar (US Regulatory) • 11/01/2023 01:31:11 PM
Lipocine to Present Clinical Data on LPCN 1148 at The Liver Meeting® 2023 • PR Newswire (US) • 11/01/2023 12:00:00 PM

More LPCN News

InvestorsHub NewsWire

NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM

ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM

Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM

Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM

Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM

Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM

Start posting your company's news

Only $200 per official company press release!

Volume
Day Range:
Bid Price
Ask Price
Last Trade Time:

Boards:

Quotes:

Boards

News

Market Data

Markets

Discover